List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2947943/publications.pdf Version: 2024-02-01



ΜΛΟΝΗς SIMPÃON

#	Article	IF	CITATIONS
1	Greater Overlap of Rome IV Disorders of Gut-Brain Interactions Leads to Increased Disease Severity and Poorer Quality of Life. Clinical Gastroenterology and Hepatology, 2022, 20, e945-e956.	4.4	52
2	Functional Gastrointestinal Disorders and Associated Health Impairment in Individuals with Celiac Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 1315-1325.e4.	4.4	9
3	Food Avoidance and Restriction in Irritable Bowel Syndrome: Relevance for Symptoms, Quality of Life and Nutrient Intake. Clinical Gastroenterology and Hepatology, 2022, 20, 1290-1298.e4.	4.4	31
4	Global Prevalence and Impact of Rumination Syndrome. Gastroenterology, 2022, 162, 731-742.e9.	1.3	12
5	Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. American Journal of Gastroenterology, 2022, 117, 147-157.	0.4	39
6	Predictors of Symptom-Specific Treatment Response to Dietary Interventions in Irritable Bowel Syndrome. Nutrients, 2022, 14, 397.	4.1	13
7	The Role of Carbohydrates in Irritable Bowel Syndrome: Protocol for a Randomized Controlled Trial Comparing Three Different Treatment Options. JMIR Research Protocols, 2022, 11, e31413.	1.0	0
8	Letter in response to Black et al. (2020). Neurogastroenterology and Motility, 2022, 34, e14329.	3.0	1
9	Health-related quality of life in patients with long-standing ulcerative colitis in remission. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482110624.	3.2	3
10	Global prevalence and burden of meal-related abdominal pain. BMC Medicine, 2022, 20, 71.	5.5	11
11	Maintaining work life under threat of symptoms: a grounded theory study of work life experiences in persons with Irritable Bowel Syndrome. BMC Gastroenterology, 2022, 22, 73.	2.0	4
12	Fecal luminal factors from patients with irritable bowel syndrome induce distinct gene expression of colonoids. Neurogastroenterology and Motility, 2022, 34, e14390.	3.0	4
13	Mechanisms Underlying Food-Triggered Symptoms in Disorders of Gut-Brain Interactions. American Journal of Gastroenterology, 2022, 117, 937-946.	0.4	10
14	Randomised clinical trial: individual versus group hypnotherapy for irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2022, 55, 1501-1511.	3.7	12
15	Serotonin type 3 receptor subunit gene polymorphisms associated with psychosomatic symptoms in irritable bowel syndrome: A multicenter retrospective study. World Journal of Gastroenterology, 2022, 28, 2334-2349.	3.3	2
16	Editorial: groupâ€based hypnotherapy as good as individually delivered hypnotherapy for symptoms of irritable bowel syndrome—authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 160-161.	3.7	0
17	Irritable bowel syndrome: Factors of importance for diseaseâ€specific quality of life. United European Gastroenterology Journal, 2022, 10, 754-764.	3.8	8
18	Normal values and regional differences in oesophageal impedance-pH metrics: a consensus analysis of impedance-pH studies from around the world. Gut, 2021, 70, 1441-1449.	12.1	49

#	Article	IF	CITATIONS
19	Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology, 2021, 160, 99-114.e3.	1.3	913
20	Prevalence and Progression of Recurrent Abdominal Pain, From Early Childhood to Adolescence. Clinical Gastroenterology and Hepatology, 2021, 19, 930-938.e8.	4.4	19
21	Rome IV Functional Gastrointestinal Disorders and Health Impairment in Subjects With Hypermobility Spectrum Disorders or Hypermobile Ehlers-Danlos Syndrome. Clinical Gastroenterology and Hepatology, 2021, 19, 277-287.e3.	4.4	29
22	Online Education Is Non-Inferior to Group Education for Irritable Bowel Syndrome: A Randomized Trial and Patient Preference Trial. Clinical Gastroenterology and Hepatology, 2021, 19, 743-751.e1.	4.4	5
23	Visceral hypersensitivity is together with psychological distress and female gender associated with severity of IBSâ€like symptoms in quiescent ulcerative colitis. Neurogastroenterology and Motility, 2021, 33, e13998.	3.0	4
24	The overlap between irritable bowel syndrome and organic gastrointestinal diseases. The Lancet Gastroenterology and Hepatology, 2021, 6, 139-148.	8.1	52
25	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 1: Epidemiology, diagnosis, clinical associations, pathophysiology and investigation. Neurogastroenterology and Motility, 2021, 33, e14050.	3.0	25
26	Association between pain sensitivity and gray matter properties in the sensorimotor network in women with irritable bowel syndrome. Neurogastroenterology and Motility, 2021, 33, e14027.	3.0	8
27	Association between <i>Brachyspira</i> and irritable bowel syndrome with diarrhoea. Gut, 2021, 70, 1117-1129.	12.1	31
28	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. Neurogastroenterology and Motility, 2021, 33, e14070.	3.0	17
29	A randomized doubleâ€blind placeboâ€controlled crossover pilot study: Acute effects of the enzyme αâ€galactosidase on gastrointestinal symptoms in irritable bowel syndrome patients. Neurogastroenterology and Motility, 2021, 33, e14094.	3.0	4
30	A novel stepwise integrative analysis pipeline reveals distinct microbiota-host interactions and link to symptoms in irritable bowel syndrome. Scientific Reports, 2021, 11, 5521.	3.3	4
31	Diet and gut microbiome interactions of relevance for symptoms in irritable bowel syndrome. Microbiome, 2021, 9, 74.	11.1	25
32	Fecal microbiota dynamics during disease activity and remission in newly diagnosed and established ulcerative colitis. Scientific Reports, 2021, 11, 8641.	3.3	9
33	Central sensitization and severity of gastrointestinal symptoms in irritable bowel syndrome, chronic pain syndromes, and inflammatory bowel disease. Neurogastroenterology and Motility, 2021, 33, e14156.	3.0	18
34	Psychometric evaluation of an experience sampling method–based patientâ€reported outcome measure in functional dyspepsia. Neurogastroenterology and Motility, 2021, 33, e14136.	3.0	7
35	A Distinct Faecal Microbiota and Metabolite Profile Linked to Bowel Habits in Patients with Irritable Bowel Syndrome. Cells, 2021, 10, 1459.	4.1	23
36	Reply: The key to success: Targeting enzymes to their dietary counterpart. Neurogastroenterology and Motility, 2021, 33, e14203.	3.0	0

#	Article	IF	CITATIONS
37	The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2021, 6, 459-473.	8.1	37
38	The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome. Journal of Cellular and Molecular Medicine, 2021, 25, 8047-8061.	3.6	5
39	Allergy-related diseases in childhood and risk for abdominal pain-related functional gastrointestinal disorders at 16 years—a birth cohort study. BMC Medicine, 2021, 19, 214.	5.5	8
40	Gluten and fructan intake and their associations with gastrointestinal symptoms in irritable bowel syndrome: A food diary study. Clinical Nutrition, 2021, 40, 5365-5372.	5.0	16
41	Cumulative Effect of Psychological Alterations on Gastrointestinal Symptom Severity in Irritable Bowel Syndrome. American Journal of Gastroenterology, 2021, 116, 769-779.	0.4	22
42	Habitual FODMAP Intake in Relation to Symptom Severity and Pattern in Patients with Irritable Bowel Syndrome. Nutrients, 2021, 13, 27.	4.1	11
43	<i>Aloe barbadensis</i> Mill. extract improves symptoms in IBS patients with diarrhoea: post hoc analysis of two randomized double-blind controlled studies. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110481.	3.2	4
44	Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population. United European Gastroenterology Journal, 2021, 9, 1178-1188.	3.8	18
45	Changes in serum and urinary metabolomic profile after a dietary intervention in patients with irritable bowel syndrome. PLoS ONE, 2021, 16, e0257331.	2.5	6
46	The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profiles and Host Mucosal Response in Patients with Irritable Bowel Syndrome. Nutrients, 2021, 13, 3836.	4.1	17
47	OTH-5â€Functional gastrointestinal disorders and associated health impairment in individuals with coeliac disease. , 2021, , .		0
48	Altered Structural Covariance of Insula, Cerebellum and Prefrontal Cortex Is Associated with Somatic Symptom Levels in Irritable Bowel Syndrome (IBS). Brain Sciences, 2021, 11, 1580.	2.3	4
49	GWAS of stool frequency provides insights into gastrointestinal motility and irritable bowel syndrome. Cell Genomics, 2021, 1, 100069.	6.5	15
50	Diagnostic Evaluation of Gastric Motor and Sensory Disorders. American Journal of Gastroenterology, 2021, 116, 2345-2356.	0.4	17
51	Fecal Incontinence Diagnosed by the Rome IV Criteria in the United States, Canada, and the United Kingdom. Clinical Gastroenterology and Hepatology, 2020, 18, 385-391.	4.4	37
52	Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. Gastroenterology, 2020, 158, 1262-1273.e3.	1.3	249
53	Systemic Inflammatory Protein Profiles Distinguish Irritable Bowel Syndrome (IBS) and Ulcerative Colitis, Irrespective of Inflammation or IBS-Like Symptoms. Inflammatory Bowel Diseases, 2020, 26, 874-884.	1.9	24
54	Adherence to diet low in fermentable carbohydrates and traditional diet for irritable bowel syndrome. Nutrition, 2020, 73, 110719.	2.4	12

#	Article	IF	CITATIONS
55	An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation. Expert Review of Gastroenterology and Hepatology, 2020, 14, 39-46.	3.0	148
56	Patient safety before and after implementing personâ€centred inpatient care — A quasiâ€experimental study. Journal of Clinical Nursing, 2020, 29, 602-612.	3.0	4
57	European society of neurogastroenterology and motility guidelines on functional constipation in adults. Neurogastroenterology and Motility, 2020, 32, e13762.	3.0	110
58	The diagnostic value of a change in bowel habit for colorectal cancer within different age groups. United European Gastroenterology Journal, 2020, 8, 211-219.	3.8	4
59	Combining symptoms and biomarkers: The future diagnostic approach for disorders of gutâ€brain interaction?. Neurogastroenterology and Motility, 2020, 32, e14019.	3.0	2
60	Functional gastrointestinal disorders are increased in joint hypermobilityâ€related disorders with concomitant postural orthostatic tachycardia syndrome. Neurogastroenterology and Motility, 2020, 32, e13975.	3.0	19
61	Responses to the Letter to the Editor by Brusciano et al Neurogastroenterology and Motility, 2020, 32, e13981.	3.0	1
62	Patient-Specific Stress–Abdominal Pain Interaction in Irritable Bowel Syndrome: An Exploratory Experience Sampling Method Study. Clinical and Translational Gastroenterology, 2020, 11, e00209.	2.5	10
63	Positive Effect of Bimodal Release Ondansetron in Irritable Bowel Syndrome With Diarrhea: Relevance of Low-Grade Inflammation?. American Journal of Gastroenterology, 2020, 115, 1976-1978.	0.4	1
64	Fecal microbiota composition is linked to the postoperative disease course in patients with Crohn's disease. BMC Gastroenterology, 2020, 20, 130.	2.0	15
65	Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, doubleâ€blind, placeboâ€controlled study. Neurogastroenterology and Motility, 2020, 32, e13920.	3.0	32
66	A survey on the impact of the COVIDâ€19 pandemic on motility and functional investigations in Europe and considerations for recommencing activities in the early recovery phase. Neurogastroenterology and Motility, 2020, 32, e13926.	3.0	14
67	Associations among neurophysiology measures in irritable bowel syndrome (IBS) and their relevance for IBS symptoms. Scientific Reports, 2020, 10, 9794.	3.3	14
68	Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology. American Journal of Gastroenterology, 2020, 115, 1007-1018.	0.4	3
69	Resting state functional connectivity of the pain matrix and default mode network in irritable bowel syndrome: a graph theoretical analysis. Scientific Reports, 2020, 10, 11015.	3.3	17
70	Foodâ€symptom diaries can generate personalized lifestyle advice for managing gastrointestinal symptoms: A pilot study. Neurogastroenterology and Motility, 2020, 32, e13820.	3.0	2
71	Evidence-based and mechanistic insights into exclusion diets for IBS. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 406-413.	17.8	46
72	Evidence of altered mucosa-associated and fecal microbiota composition in patients with Irritable Bowel Syndrome. Scientific Reports, 2020, 10, 593.	3.3	37

#	Article	IF	CITATIONS
73	Randomized clinical trial: Effects of <i>Aloe barbadensis</i> Mill. extract on symptoms, fecal microbiota and fecal metabolite profiles in patients with irritable bowel syndrome. Neurogastroenterology and Motility, 2020, 32, e13860.	3.0	10
74	Human Milk Oligosaccharides Support Normal Bowel Function and Improve Symptoms of Irritable Bowel Syndrome: A Multicenter, Open-Label Trial. Clinical and Translational Gastroenterology, 2020, 11, e00276.	2.5	19
75	A Pilot Study of the Effect of Aloe barbadensis Mill. Extract (AVH200®) in Patients with Irritable Bowel Syndrome: a Randomized, Double-Blind, Placebo-Controlled Study. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 275-280.	0.9	29
76	Small Intestinal Bacterial Overgrowth. , 2020, , 454-458.		0
77	Epidemiology, Clinical Characteristics, and Associations for Rome IV Functional Nausea and Vomiting Disorders in Adults. Clinical Gastroenterology and Hepatology, 2019, 17, 878-886.	4.4	93
78	Muscle performance and fatigue in compensated chronic liver disease. Scandinavian Journal of Gastroenterology, 2019, 54, 925-933.	1.5	6
79	Cumulative Effects of Psychologic Distress, Visceral Hypersensitivity, and Abnormal Transit on Patient-reported Outcomes in Irritable Bowel Syndrome. Gastroenterology, 2019, 157, 391-402.e2.	1.3	81
80	The role of diet in irritable bowel syndrome: implications for dietary advice. Journal of Internal Medicine, 2019, 286, 490-502.	6.0	47
81	Colonic mast cell numbers, symptom profile, and mucosal expression of elements of the epithelial barrier in irritable bowel syndrome. Neurogastroenterology and Motility, 2019, 31, e13701.	3.0	10
82	The Dietary Management of Patients with Irritable Bowel Syndrome: A Narrative Review of the Existing and Emerging Evidence. Nutrients, 2019, 11, 2162.	4.1	59
83	Effects of the long-term storage of human fecal microbiota samples collected in RNAlater. Scientific Reports, 2019, 9, 601.	3.3	36
84	Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterology, 2019, 19, 69.	2.0	67
85	Anxiety and depression in irritable bowel syndrome: Exploring the interaction with other symptoms and pathophysiology using multivariate analyses. Neurogastroenterology and Motility, 2019, 31, e13619.	3.0	66
86	Relations between food intake, psychological distress, and gastrointestinal symptoms: A diary study. United European Gastroenterology Journal, 2019, 7, 965-973.	3.8	19
87	Visceral sensitivity remains stable over time in patients with irritable bowel syndrome, but with individual fluctuations. Neurogastroenterology and Motility, 2019, 31, e13603.	3.0	8
88	Evidence for an association of gut microbial Clostridia with brain functional connectivity and gastrointestinal sensorimotor function in patients with irritable bowel syndrome, based on tripartite network analysis. Microbiome, 2019, 7, 45.	11.1	83
89	Symptoms compatible with functional bowel disorders are common in patients with quiescent ulcerative colitis and influence the quality of life but not the course of the disease. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481982768.	3.2	9
90	Mucosal and Systemic Immune Profiles Differ During Early and Late Phases of the Disease in Patients With Active Ulcerative Colitis. Journal of Crohn's and Colitis, 2019, 13, 1450-1458.	1.3	16

#	Article	IF	CITATIONS
91	Fasting breath H2 and gut microbiota metabolic potential are associated with the response to a fermented milk product in irritable bowel syndrome. PLoS ONE, 2019, 14, e0214273.	2.5	12
92	Person entred inpatient care – A quasiâ€experimental study in an internal medicine context. Journal of Advanced Nursing, 2019, 75, 1678-1689.	3.3	10
93	Clinical and Cost Effectiveness of Online Cognitive Behavioral Therapy in Children With Functional Abdominal Pain Disorders. Clinical Gastroenterology and Hepatology, 2019, 17, 2236-2244.e11.	4.4	48
94	Within- and Between-Subject Variation in Dietary Intake of Fermentable Oligo-, Di-, Monosaccharides, and Polyols Among Patients with Irritable Bowel Syndrome. Current Developments in Nutrition, 2019, 3, nzy101.	0.3	13
95	Undergoing repeated colonoscopies – experiences from patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2019, 54, 1467-1472.	1.5	9
96	An Intervention for Person-Centered Support in Irritable Bowel Syndrome. Gastroenterology Nursing, 2019, 42, 332-341.	0.4	1
97	Subgroups of IBS patients are characterized by specific, reproducible profiles of GI and nonâ€GI symptoms and report differences in healthcare utilization: A populationâ€based study. Neurogastroenterology and Motility, 2019, 31, e13483.	3.0	28
98	Development of a realâ€ŧime patientâ€ŧeported outcome measure for symptom assessment in patients with functional dyspepsia using the experience sampling method. Neurogastroenterology and Motility, 2019, 31, e13496.	3.0	12
99	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 1002-1004.	4.4	0
100	Evidence of increased fecal granins in children with irritable bowel syndrome and correlates with symptoms. Neurogastroenterology and Motility, 2019, 31, e13486.	3.0	5
101	Validation of Fatigue Impact Scale with various item sets – a Rasch analysis. Disability and Rehabilitation, 2019, 41, 840-846.	1.8	13
102	Increased Prevalence of Rare Sucrase-isomaltase PathogenicÂVariants in Irritable Bowel Syndrome Patients. Clinical Gastroenterology and Hepatology, 2018, 16, 1673-1676.	4.4	64
103	Development of Irritable Bowel Syndrome Features Over a 5-year Period. Clinical Gastroenterology and Hepatology, 2018, 16, 1244-1251.e1.	4.4	18
104	Health problems associated with irritable bowel syndrome: analysis of a primary care registry. Alimentary Pharmacology and Therapeutics, 2018, 47, 1349-1357.	3.7	10
105	Heart rate variability characteristics of patients with irritable bowel syndrome and associations with symptoms. Neurogastroenterology and Motility, 2018, 30, e13320.	3.0	22
106	Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. The Lancet Gastroenterology and Hepatology, 2018, 3, 252-262.	8.1	199
107	Psychological distress, iron deficiency, active disease and female gender are independent risk factors for fatigue in patients with ulcerative colitis. United European Gastroenterology Journal, 2018, 6, 148-158.	3.8	25
108	Functional Dyspepsia and Severity of Psychologic Symptoms Associate With Postprandial Symptoms in Patients With IrritableÂBowel Syndrome. Clinical Gastroenterology and Hepatology, 2018, 16, 1745-1753.e1.	4.4	21

#	Article	IF	CITATIONS
109	Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. Gastroenterology, 2018, 155, 168-179.	1.3	55
110	Factor Analysis Defines Distinct Upper and Lower Gastrointestinal Symptom Groups Compatible With Rome IV Criteria in a Population-based Study. Clinical Gastroenterology and Hepatology, 2018, 16, 1252-1259.e5.	4.4	18
111	Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. Gut, 2018, 67, 872-881.	12.1	176
112	Functional variants in the sucrase–isomaltase gene associate with increased risk of irritable bowel syndrome. Gut, 2018, 67, 263-270.	12.1	120
113	Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts. Gut, 2018, 67, 255-262.	12.1	186
114	Relationships between psychological state, abuse, somatization and visceral pain sensitivity in irritable bowel syndrome. United European Gastroenterology Journal, 2018, 6, 300-309.	3.8	20
115	Colonic immune cells in irritable bowel syndrome: A systematic review and metaâ€∎nalysis. Neurogastroenterology and Motility, 2018, 30, e13192.	3.0	119
116	The endoscopic surveillance of the transplanted small intestine: a single center experience and a proposal for a grading score. Scandinavian Journal of Gastroenterology, 2018, 53, 134-139.	1.5	14
117	Development, content validity, and crossâ€cultural adaptation of a patientâ€reported outcome measure for realâ€time symptom assessment in irritable bowel syndrome. Neurogastroenterology and Motility, 2018, 30, e13244.	3.0	20
118	The Prevalence and Impact of Overlapping Rome IV-Diagnosed Functional Gastrointestinal Disorders on Somatization, Quality of Life, and Healthcare Utilization: A Cross-Sectional General Population Study in Three Countries. American Journal of Gastroenterology, 2018, 113, 86-96.	0.4	138
119	Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts. Gut, 2018, 67, 1425-1433.	12.1	27
120	Oesophageal symptoms are common and associated with other functional gastrointestinal disorders (FGIDs) in an Englishâ€speaking Western population. United European Gastroenterology Journal, 2018, 6, 1461-1469.	3.8	10
121	Fecal chromogranins and secretogranins are linked to the fecal and mucosal intestinal bacterial composition of IBS patients and healthy subjects. Scientific Reports, 2018, 8, 16821.	3.3	10
122	Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem. American Journal of Gastroenterology, 2018, 113, 1540-1549.	0.4	127
123	Altered intestinal antibacterial gene expression response profile in irritable bowel syndrome is linked to bacterial composition and immune activation. Neurogastroenterology and Motility, 2018, 30, e13468.	3.0	15
124	Manipulating the Gut Microbiome as a Treatment Strategy forÂFunctional Gastrointestinal Disorders. Gastroenterology, 2018, 155, 960-962.	1.3	11
125	Systemic cytokines are elevated in a subset of patients with irritable bowel syndrome but largely unrelated to symptom characteristics. Neurogastroenterology and Motility, 2018, 30, e13378.	3.0	16
126	New treatments and therapeutic targets for IBS and other functional bowel disorders. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 589-605.	17.8	99

#	Article	IF	CITATIONS
127	Pre―and perinatal stress and irritable bowel syndrome in young adults – A nationwide registerâ€based cohort study. Neurogastroenterology and Motility, 2018, 30, e13436.	3.0	11
128	Funding for gastrointestinal disease research in the European Union. The Lancet Gastroenterology and Hepatology, 2018, 3, 593-595.	8.1	9
129	Neither selfâ€reported atopy nor IgEâ€mediated allergy are linked to gastrointestinal symptoms in patients with irritable bowel syndrome. Neurogastroenterology and Motility, 2018, 30, e13379.	3.0	17
130	How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors. American Journal of Gastroenterology, 2018, 113, 1017-1025.	0.4	90
131	Integrity of central nervous function in diabetes mellitus assessed by resting state EEG frequency analysis and source localization. Journal of Diabetes and Its Complications, 2017, 31, 400-406.	2.3	12
132	Management of the multiple symptoms of irritable bowel syndrome. The Lancet Gastroenterology and Hepatology, 2017, 2, 112-122.	8.1	54
133	<i>TRPM8</i> polymorphisms associated with increased risk of IBS-C and IBS-M. Gut, 2017, 66, 1725-1727.	12.1	36
134	European consensus conference on faecal microbiota transplantation in clinical practice. Gut, 2017, 66, 569-580.	12.1	793
135	Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management?. Expert Review of Gastroenterology and Hepatology, 2017, 11, 281-283.	3.0	46
136	Understanding the Gut Microbiota in Inflammatory and Functional Gastrointestinal Diseases. Psychosomatic Medicine, 2017, 79, 857-867.	2.0	43
137	Small intestinal bacterial overgrowth as a cause for irritable bowel syndrome. Current Opinion in Gastroenterology, 2017, 33, 196-202.	2.3	37
138	An expert consensus definition of failure of a treatment to provide adequate relief (Fâ€∢scp>PAR) for chronic constipation – an international Delphi survey. Alimentary Pharmacology and Therapeutics, 2017, 45, 434-442.	3.7	11
139	Effects of conventional and a novel colonicâ€release bile acid sequestrant, A3384, on fibroblast growth factor 19 and bile acid metabolism in healthy volunteers and patients with bile acid diarrhoea. United European Gastroenterology Journal, 2017, 5, 380-388.	3.8	9
140	The Mucosal Antibacterial Response Profile and Fecal Microbiota Composition Are Linked to the Disease Course in Patients with Newly Diagnosed Ulcerative Colitis. Inflammatory Bowel Diseases, 2017, 23, 956-966.	1.9	17
141	Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. Current Gastroenterology Reports, 2017, 19, 15.	2.5	181
142	A Perspective on Brain–Gut Communication: The American Gastroenterology Association and American Psychosomatic Society Joint Symposium on Brain–Gut Interactions and the Intestinal Microenvironment. Psychosomatic Medicine, 2017, 79, 847-856.	2.0	23
143	Coping Skills Are Associated With Gastrointestinal Symptom Severity and Somatization in Patients With Irritable BowelÂSyndrome. Clinical Gastroenterology and Hepatology, 2017, 15, 1565-1571.e3.	4.4	27
144	Patient preferences for endpoints in fecal incontinence treatment studies. Neurogastroenterology and Motility, 2017, 29, e13032.	3.0	11

#	Article	IF	CITATIONS
145	miR-16 and miR-103 impact 5-HT4 receptor signalling and correlate with symptom profile in irritable bowel syndrome. Scientific Reports, 2017, 7, 14680.	3.3	46
146	Editorial: subgroups in irritable bowel syndrome—more than just diarrhoea and constipation? Authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 698-699.	3.7	1
147	Mixture model analysis identifies irritable bowel syndrome subgroups characterised by specific profiles of gastrointestinal, extraintestinal somatic and psychological symptoms. Alimentary Pharmacology and Therapeutics, 2017, 46, 529-539.	3.7	35
148	Chronic constipation. Nature Reviews Disease Primers, 2017, 3, 17095.	30.5	203
149	Breath Testing Consensus Guidelines for SIBO: RES IPSA LOCQUITOR. American Journal of Gastroenterology, 2017, 112, 1888-1889.	0.4	7
150	How to get your work published: Tricks and pearls. United European Gastroenterology Journal, 2017, 5, 300-301.	3.8	0
151	Fecal incontinence in irritable bowel syndrome: Prevalence and associated factors in Swedish and American patients. Neurogastroenterology and Motility, 2017, 29, e12919.	3.0	23
152	Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome. Gastroenterology, 2017, 152, 111-123.e8.	1.3	470
153	Fatigue: a distressing symptom for patients with irritable bowel syndrome. Neurogastroenterology and Motility, 2017, 29, e12898.	3.0	27
154	Internet-Delivered Cognitive Behavior Therapy for Adolescents With Irritable Bowel Syndrome: A Randomized Controlled Trial. American Journal of Gastroenterology, 2017, 112, 152-162.	0.4	96
155	Autonomic nervous system function predicts the inflammatory response over three years in newly diagnosed ulcerative colitis patients. Neurogastroenterology and Motility, 2016, 28, 1655-1662.	3.0	25
156	Biomarkers to distinguish functional constipation from irritable bowel syndrome with constipation. Neurogastroenterology and Motility, 2016, 28, 783-792.	3.0	17
157	Phenotyping of subjects for large scale studies on patients with <scp>IBS</scp> . Neurogastroenterology and Motility, 2016, 28, 1134-1147.	3.0	36
158	Treating Fecal Incontinence: An Unmet Need in Primary Care Medicine. North Carolina Medical Journal, 2016, 77, 211-215.	0.2	19
159	News from the editors of Neurogastroenterology and Motility. Neurogastroenterology and Motility, 2016, 28, 1451-1451.	3.0	0
160	IBS-like Symptoms in Patients with Ulcerative Colitis in Deep Remission Are Associated with Increased Levels of Serum Cytokines and Poor Psychological Well-being. Inflammatory Bowel Diseases, 2016, 22, 2630-2640.	1.9	71
161	Reply. Clinical Gastroenterology and Hepatology, 2016, 14, 1222-1223.	4.4	0
162	Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction–Recommendations of the Nordic Working Group. Scandinavian Journal of Pain, 2016, 11, 111-122.	1.3	73

#	Article	IF	CITATIONS
163	Bowel Disorders. Gastroenterology, 2016, 150, 1393-1407.e5.	1.3	1,912
164	Centrally Mediated Disorders of Gastrointestinal Pain. Gastroenterology, 2016, 150, 1408-1419.	1.3	102
165	Altered expression of Butyrophilin ( <i>BTN</i> ) and BTNâ€like ( <i>BTNL</i> ) genes in intestinal inflammation and Disease, 2016, 4, 191-200.	2.7	65
166	Irritable bowel syndrome. Nature Reviews Disease Primers, 2016, 2, 16014.	30.5	674
167	Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome. American Journal of Gastroenterology, 2016, 111, 1165-1176.	0.4	86
168	Patients' experiences of healthcare encounters in severe irritable bowel syndrome: an analysis based on narrative and feminist theory. Journal of Clinical Nursing, 2016, 25, 2967-2978.	3.0	19
169	Review article: bile acid diarrhoea – pathogenesis, diagnosis and management. Alimentary Pharmacology and Therapeutics, 2016, 43, 884-898.	3.7	83
170	Reply. Gastroenterology, 2016, 150, 1047-1048.	1.3	0
171	Lactulose Challenge Determines Visceral Sensitivity and Severity of Symptoms in Patients With Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2016, 14, 226-233.e3.	4.4	38
172	Depression and Somatization Are Associated With Increased Postprandial Symptoms in Patients With Irritable BowelÂSyndrome. Gastroenterology, 2016, 150, 866-874.	1.3	71
173	In search for a disease-modifying treatment in irritable bowel syndrome. Gut, 2016, 65, 2-3.	12.1	6
174	Practical management of irritable bowel syndrome: a clinical review. Minerva Gastroenterologica E Dietologica, 2016, 62, 30-48.	2.2	10
175	The severity of inflammation at onset of ulcerative colitis is not associated with IBS-like symptoms during clinical remission. Journal of Crohn's and Colitis, 2015, 9, 776-783.	1.3	11
176	A randomized, doubleâ€blind, placeboâ€controlled trial to evaluate the efficacy, safety, and tolerability of longâ€ŧerm treatment with prucalopride. Neurogastroenterology and Motility, 2015, 27, 805-815.	3.0	49
177	UEG Week in Vienna 2016—advancing science, linking people. United European Gastroenterology Journal, 2015, 3, 484-484.	3.8	0
178	Reflecting on a memorable UEG Week 2015…. United European Gastroenterology Journal, 2015, 3, 572-572.	3.8	0
179	Psychological factors selectively upregulate rectal pain perception in hypersensitive patients with irritable bowel syndrome. Neurogastroenterology and Motility, 2015, 27, 1772-1782.	3.0	33
180	The Short Health Scale. Journal of Clinical Gastroenterology, 2015, 49, 565-570.	2.2	10

#	Article	IF	CITATIONS
181	Impact factor increases to its highest level ever. Neurogastroenterology and Motility, 2015, 27, 1051-1051.	3.0	1
182	More similarities than differences between men and women with irritable bowel syndrome. Neurogastroenterology and Motility, 2015, 27, 796-804.	3.0	23
183	Gut Microbiota as Potential Orchestrators of Irritable Bowel Syndrome. Gut and Liver, 2015, 9, 318-31.	2.9	114
184	Authors' response: Bile acids are important in the pathophysiology of IBS. Gut, 2015, 64, 851.2-852.	12.1	1
185	Nurse-Administered, Gut-Directed Hypnotherapy in IBS: Efficacy and Factors Predicting a Positive Response. American Journal of Clinical Hypnosis, 2015, 58, 100-114.	0.6	20
186	Fifteen years' experience of intestinal and multivisceral transplantation in the Nordic countries. Scandinavian Journal of Gastroenterology, 2015, 50, 278-290.	1.5	30
187	Are the definitions for chronic diarrhoea adequate? Evaluation of two different definitions in patients with chronic diarrhoea. United European Gastroenterology Journal, 2015, 3, 381-386.	3.8	24
188	Gastrointestinal motility and neurogastroenterology. Scandinavian Journal of Gastroenterology, 2015, 50, 685-697.	1.5	6
189	Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial. Gastroenterology, 2015, 149, 1399-1407.e2.	1.3	463
190	Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Alimentary Pharmacology and Therapeutics, 2015, 42, 71-83.	3.7	218
191	Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 36-49.	17.8	147
192	Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut, 2015, 64, 84-92.	12.1	167
193	Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. Gut, 2015, 64, 1774-1782.	12.1	97
194	Postprandial Plasma Glucose Response and Gastrointestinal Symptom Severity in Patients With Diabetic Gastroparesis. Journal of Diabetes Science and Technology, 2014, 8, 881-888.	2.2	8
195	IBS with intestinal microbial dysbiosis: a new and clinically relevant subgroup?. Gut, 2014, 63, 1685-1686.	12.1	20
196	Genetic variants in <i>CDC42</i> and <i>NXPH1</i> as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome. Gut, 2014, 63, 1103-1111.	12.1	49
197	Gut microbiota and neurogastroenterology and motility: the good the bad and the ugly. Neurogastroenterology and Motility, 2014, 26, 295-295.	3.0	2
198	The gendered impact of Irritable Bowel Syndrome: a qualitative study of patients' experiences. Journal of Advanced Nursing, 2014, 70, 1334-1343.	3.3	29

#	Article	IF	CITATIONS
199	Use of antibiotics in infancy and childhood and risk of recurrent abdominal pain—a <scp>S</scp> wedish birth cohort study. Neurogastroenterology and Motility, 2014, 26, 841-850.	3.0	31
200	Interaction between preprandial and postprandial rectal sensory and motor abnormalities in IBS. Gut, 2014, 63, 1441-1449.	12.1	41
201	Rectal Sensitivity in Diabetes Patients with Symptoms of Gastroparesis. Journal of Diabetes Research, 2014, 2014, 1-8.	2.3	18
202	Allergyâ€related diseases and recurrent abdominal pain during childhood – a birth cohort study. Alimentary Pharmacology and Therapeutics, 2014, 40, 1349-1358.	3.7	28
203	Cytokine imbalance in irritable bowel syndrome: a systematic review and metaâ€analysis. Neurogastroenterology and Motility, 2014, 26, 1036-1048.	3.0	130
204	Internet-delivered cognitive behavior therapy for adolescents with functional gastrointestinal disorders — An open trial. Internet Interventions, 2014, 1, 141-148.	2.7	24
205	A Small Particle Size Diet Reduces Upper Gastrointestinal Symptoms in Patients With Diabetic Gastroparesis: A Randomized Controlled Trial. American Journal of Gastroenterology, 2014, 109, 375-385.	0.4	155
206	Diet as a Therapy for Irritable Bowel Syndrome: Progress at Last. Gastroenterology, 2014, 146, 10-12.	1.3	18
207	Association between visceral, cardiac and sensorimotor polyneuropathies in diabetes mellitus. Journal of Diabetes and Its Complications, 2014, 28, 370-377.	2.3	36
208	Self-Reported Food-Related Gastrointestinal Symptoms in IBS Are Common and Associated With More Severe Symptoms and Reduced Quality of Life. American Journal of Gastroenterology, 2013, 108, 634-641.	0.4	469
209	Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain. Scandinavian Journal of Gastroenterology, 2013, 48, 274-284.	1.5	71
210	Moderate hyperkalemia in hospitalized patients with cirrhotic ascites indicates a poor prognosis. Scandinavian Journal of Gastroenterology, 2013, 48, 358-365.	1.5	9
211	Nutrient intake in patients with irritable bowel syndrome compared with the general population. Neurogastroenterology and Motility, 2013, 25, 23.	3.0	77
212	Brain networks encoding rectal sensation in type 1 diabetes. Neuroscience, 2013, 237, 96-105.	2.3	21
213	In Functional Dyspepsia, Hypersensitivity to Postprandial Distention Correlates With Meal-Related Symptom Severity. Gastroenterology, 2013, 145, 566-573.	1.3	91
214	Fecal chromogranins and secretogranins are increased in patients with ulcerative colitis but are not associated with disease activity. Journal of Crohn's and Colitis, 2013, 7, e615-e622.	1.3	17
215	Randomised clinical trial: symptoms of the irritable bowel syndrome are improved by a psychoâ $\in$ education group intervention. Alimentary Pharmacology and Therapeutics, 2013, 37, 304-315.	3.7	53
216	Patient satisfaction after gutâ€directed hypnotherapy in irritable bowel syndrome. Neurogastroenterology and Motility, 2013, 25, 169.	3.0	27

#	Article	IF	CITATIONS
217	Intestinal Microbiota and its Role in Irritable Bowel Syndrome (IBS). Current Gastroenterology Reports, 2013, 15, 323.	2.5	104
218	A Combined Nutrient and Lactulose Challenge Test Allows Symptom-Based Clustering of Patients With Irritable Bowel Syndrome. American Journal of Gastroenterology, 2013, 108, 786-795.	0.4	35
219	UEG Week Vienna 2014: New horizons, fresh ideas. United European Gastroenterology Journal, 2013, 1, 403-404.	3.8	Ο
220	Macrostructural Brain Changes in Patients with Longstanding Type 1 Diabetes Mellitus - a Cortical Thickness Analysis Study. Experimental and Clinical Endocrinology and Diabetes, 2013, 121, 354-360.	1.2	26
221	Survival of patients evaluated for intestinal and multivisceral transplantation – the Scandinavian experience. Scandinavian Journal of Gastroenterology, 2013, 48, 702-711.	1.5	15
222	How patients with long-term experience of living with irritable bowel syndrome manage illness in daily life. European Journal of Gastroenterology and Hepatology, 2013, 25, 1478-1483.	1.6	26
223	Serum IL-17A in Newly Diagnosed Treatment-Naive Patients with Ulcerative Colitis Reflects Clinical Disease Severity and Predicts the Course of Disease. Inflammatory Bowel Diseases, 2013, 19, 2433-2439.	1.9	35
224	The Importance of a Person-Centered Approach in Diagnostic Workups of Patients With Irritable Bowel Syndrome. Gastroenterology Nursing, 2013, 36, 443-451.	0.4	12
225	Altered Brain Microstructure Assessed by Diffusion Tensor Imaging in Patients With Diabetes and Gastrointestinal Symptoms. Diabetes Care, 2013, 36, 662-668.	8.6	33
226	Factors affecting satisfaction with treatment in European women with chronic constipation: An internet survey. United European Gastroenterology Journal, 2013, 1, 375-384.	3.8	30
227	CD25 and TNF receptor II reflect early primary response to infliximab therapy in patients with ulcerative colitis. United European Gastroenterology Journal, 2013, 1, 467-476.	3.8	10
228	Hot topics in gut microbiota. United European Gastroenterology Journal, 2013, 1, 311-318.	3.8	50
229	Measurement of gastric emptying by radiopaque markers in patients with diabetes: correlation with scintigraphy and upper gastrointestinal symptoms. Neurogastroenterology and Motility, 2013, 25, e224-32.	3.0	33
230	Exploration of the effects of gender and mild esophagitis on esophageal pain thresholds in the normal and sensitized state of asymptomatic young volunteers. Neurogastroenterology and Motility, 2013, 25, 766.	3.0	9
231	Introducing our Associates. Neurogastroenterology and Motility, 2013, 25, 277-277.	3.0	Ο
232	Infliximab Inhibits Activation and Effector Functions of Peripheral Blood <scp>T</scp> Cells <i>in vitro</i> from Patients with Clinically Active Ulcerative Colitis. Scandinavian Journal of Immunology, 2013, 78, 275-284.	2.7	28
233	Neurogastroenterology and Motility going online only in January 2014. Neurogastroenterology and Motility, 2013, 25, 925-926.	3.0	0
234	Characterization of <scp>IBS</scp> â€like symptoms in patients with ulcerative colitis in clinical remission. Neurogastroenterology and Motility, 2013, 25, 756.	3.0	63

#	Article	IF	CITATIONS
235	Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut, 2013, 62, 159-176.	12.1	776
236	Diabetic Autonomic Neuropathy Affects Symptom Generation and Brain-Gut Axis. Diabetes Care, 2013, 36, 3698-3705.	8.6	54
237	Symptom pattern following a meal challenge test in patients with irritable bowel syndrome and healthy controls. United European Gastroenterology Journal, 2013, 1, 358-367.	3.8	33
238	Fecal Calprotectin Levels Predict the Clinical Course in Patients With New Onset of Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 576-581.	1.9	54
239	Long-term effects of hypnotherapy in patients with refractory irritable bowel syndrome. Scandinavian Journal of Gastroenterology, 2012, 47, 414-421.	1.5	50
240	Effects on gastrointestinal transit and antroduodenojejunal manometry after gut-directed hypnotherapy in irritable bowel syndrome (IBS). Scandinavian Journal of Gastroenterology, 2012, 47, 1480-1487.	1.5	9
241	The microbiota link to irritable bowel syndrome. Gut Microbes, 2012, 3, 572-576.	9.8	102
242	Altered Levels of Fecal Chromogranins and Secretogranins in IBS: Relevance for Pathophysiology and Symptoms?. American Journal of Gastroenterology, 2012, 107, 440-447.	0.4	55
243	Effects of Gut-Directed Hypnotherapy on IBS in Different Clinical Settings—Results From Two Randomized, Controlled Trials. American Journal of Gastroenterology, 2012, 107, 276-285.	0.4	100
244	Colonic Transit Time and IBS Symptoms: What's the Link?. American Journal of Gastroenterology, 2012, 107, 754-760.	0.4	144
245	Increased TLR2 expression on blood monocytes in irritable bowel syndrome patients. European Journal of Gastroenterology and Hepatology, 2012, 24, 1.	1.6	21
246	A Global Perspective on Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2012, 46, 356-366.	2.2	124
247	A comparison of a short nurse-based and a long multidisciplinary version of structured patient education in irritable bowel syndrome. European Journal of Gastroenterology and Hepatology, 2012, 24, 950-957.	1.6	28
248	An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut, 2012, 61, 997-1006.	12.1	742
249	Revisiting concepts of visceral nociception in irritable bowel syndrome. European Journal of Pain, 2012, 16, 1444-1454.	2.8	37
250	Modality specific alterations of esophageal sensitivity caused by longstanding diabetes mellitus. Scandinavian Journal of Pain, 2012, 3, 181-182.	1.3	0
251	Tu1437 Autonomic Nervous Function Assessed by Two Complementary Methods -Baroreceptor Sensitivity and Heart Rate Variability - in Patients With Irritable Bowel Syndrome (IBS). Gastroenterology, 2012, 142, S-832.	1.3	2
252	Meditation over Medication for Irritable Bowel Syndrome? On Exercise and Alternative Treatments for Irritable Bowel Syndrome. Current Gastroenterology Reports, 2012, 14, 283-289.	2.5	22

#	Article	IF	CITATIONS
253	Shortâ€ŧerm stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification. Alimentary Pharmacology and Therapeutics, 2012, 35, 350-359.	3.7	52
254	Commentary: shortâ€ŧerm stability of subtypes in the irritable bowel syndromes – authors' reply. Alimentary Pharmacology and Therapeutics, 2012, 35, 850-851.	3.7	0
255	The Rome II and Rome III criteria identify the same subtypeâ€populations in irritable bowel syndrome: agreement depends on the method used for symptom report. Neurogastroenterology and Motility, 2012, 24, 604.	3.0	17
256	Esophageal distension parameters as potential biomarkers of impaired gastrointestinal function in diabetes patients. Neurogastroenterology and Motility, 2012, 24, 1016.	3.0	20
257	Effect of heavy exercise on gastrointestinal transit in endurance athletes. Scandinavian Journal of Gastroenterology, 2011, 46, 673-677.	1.5	51
258	Physical Activity Improves Symptoms in Irritable Bowel Syndrome: A Randomized Controlled Trial. American Journal of Gastroenterology, 2011, 106, 915-922.	0.4	316
259	Association of TNFSF15 polymorphism with irritable bowel syndrome. Gut, 2011, 60, 1671-1677.	12.1	109
260	Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation - a double-blind study. Alimentary Pharmacology and Therapeutics, 2011, 34, 41-50.	3.7	100
261	Oxytocin reduces satiety scores without affecting the volume of nutrient intake or gastric emptying rate in healthy subjects. Neurogastroenterology and Motility, 2011, 23, 56-e5.	3.0	22
262	Diagnosis and treatment of chronic constipation - a European perspective. Neurogastroenterology and Motility, 2011, 23, 697-710.	3.0	239
263	Review article: endpoints used in functional dyspepsia drug therapy trials. Alimentary Pharmacology and Therapeutics, 2011, 33, 634-649.	3.7	62
264	Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Alimentary Pharmacology and Therapeutics, 2011, 33, 1113-1122.	3.7	123
265	Mindfulness-based stress reduction in patients with irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2011, 34, 578-579.	3.7	3
266	Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterology and Motility, 2011, 23, 8-23.	3.0	305
267	The Esophageal Multimodal Pain Model: Normal Values and Degree of Sensitization in Healthy Young Male Volunteers. Digestive Diseases and Sciences, 2011, 56, 1967-1975.	2.3	14
268	A GC–MS-based metabonomic investigation of blood serum from irritable bowel syndrome patients undergoing intervention with acidified milk products. European Food Research and Technology, 2011, 233, 1013-1021.	3.3	18
269	Temporary Percutaneous Gastric Electrical Stimulation: A Novel Technique Tested in Patients with Non-Established Indications for Gastric Electrical Stimulation. Digestion, 2011, 83, 3-12.	2.3	23
270	Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome – a randomized, doubleâ€blind, controlled study. Alimentary Pharmacology and Therapeutics, 2010, 31, 218-227.	3.7	132

#	Article	IF	CITATIONS
271	Structured patient education is superior to written information in the management of patients with irritable bowel syndrome: a randomized controlled study. European Journal of Gastroenterology and Hepatology, 2010, 22, 420-428.	1.6	72
272	The relationship between symptoms, body mass index, gastrointestinal transit and stool frequency in patients with irritable bowel syndrome. European Journal of Gastroenterology and Hepatology, 2010, 22, 102-108.	1.6	65
273	A slow caloric satiety drinking test in patients with temporary and permanent gastric electrical stimulation. European Journal of Gastroenterology and Hepatology, 2010, 22, 926-932.	1.6	5
274	Probiotics in irritable bowel syndrome: underachievers or underpowered? authors' reply. Alimentary Pharmacology and Therapeutics, 2010, 31, 923-924.	3.7	17
275	Gastrointestinal-specific anxiety: an important factor for severity of GI symptoms and quality of life in IBS. Neurogastroenterology and Motility, 2010, 22, 646-e179.	3.0	134
276	The Serum Metabolite Response to Diet Intervention with Probiotic Acidified Milk in Irritable Bowel Syndrome Patients Is Indistinguishable from that of Non-Probiotic Acidified Milk by 1H NMR-Based Metabonomic Analysis. Nutrients, 2010, 2, 1141-1155.	4.1	16
277	Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 163-173.	17.8	522
278	T-Cell Activation in Patients With Irritable Bowel Syndrome. American Journal of Gastroenterology, 2009, 104, 1205-1212.	0.4	145
279	Review: Altering the gastrointestinal flora in patients with functional bowel disorders: a way ahead?. Therapeutic Advances in Gastroenterology, 2009, 2, S5-S8.	3.2	0
280	Development of an educational intervention for patients with Irritable Bowel Syndrome (IBS) – a pilot study. BMC Gastroenterology, 2009, 9, 10.	2.0	30
281	Bâ€cell activation in patients with irritable bowel syndrome (IBS). Neurogastroenterology and Motility, 2009, 21, 644.	3.0	65
282	Indirect evidence for increased mechanosensitivity of jejunal secretomotor neurones in patients with idiopathic bile acid malabsorption. Acta Physiologica, 2009, 197, 129-137.	3.8	12
283	Hypervigilance in irritable bowel syndrome compared with organic gastrointestinal disease. Journal of Psychosomatic Research, 2009, 66, 399-405.	2.6	44
284	Peripheral factors in the pathophysiology of irritable bowel syndrome. Digestive and Liver Disease, 2009, 41, 788-793.	0.9	44
285	Bloating and Abdominal Distention: Not So Poorly Understood Anymore!. Gastroenterology, 2009, 136, 1487-1490.	1.3	13
286	Impact of dialysis on gastroesophageal reflux, dyspepsia, and proton pump inhibitor treatment in patients with chronic renal failure. European Journal of Gastroenterology and Hepatology, 2009, 21, 137-142.	1.6	21
287	What Do Patients With Irritable Bowel Syndrome Know About Their Disorder and How Do They Use Their Knowledge?. Gastroenterology Nursing, 2009, 32, 284-292.	0.4	12
288	Gastrointestinal transit abnormalities are frequently detected in patients with unexplained GI symptoms at a tertiary centre. Neurogastroenterology and Motility, 2008, 20, 197-205.	3.0	68

#	Article	IF	CITATIONS
289	Predictors of subjective fatigue in chronic gastrointestinal disease. Alimentary Pharmacology and Therapeutics, 2008, 28, 638-647.	3.7	40
290	Methods to assess gastric motility and sensation. Scandinavian Journal of Gastroenterology, 2008, 43, 1285-1295.	1.5	19
291	A pilot study of colonic B cell pattern in irritable bowel syndrome. Scandinavian Journal of Gastroenterology, 2008, 43, 1461-1466.	1.5	24
292	Efficient diagnosis of suspected functional bowel disorders. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 498-507.	1.7	19
293	Altered bile acid metabolism in patients with constipation-predominant irritable bowel syndrome and functional constipation. Scandinavian Journal of Gastroenterology, 2008, 43, 1483-1488.	1.5	54
294	Prevalence of gastrointestinal symptoms in patients with chronic obstructive pulmonary disease. European Journal of Gastroenterology and Hepatology, 2008, 20, 335-341.	1.6	28
295	Why do subjects with irritable bowel syndrome seek health care for their symptoms?. Scandinavian Journal of Gastroenterology, 2007, 42, 1194-1203.	1.5	59
296	Role of gastric sensorimotor dysfunction in gastrointestinal symptoms and energy intake in liver cirrhosis. Scandinavian Journal of Gastroenterology, 2007, 42, 237-246.	1.5	21
297	Abdominal tenderness in ascites patients indicates spontaneous bacterial peritonitis. European Journal of Internal Medicine, 2007, 18, 44-47.	2.2	13
298	Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut, 2007, 56, 802-808.	12.1	431
299	Lipid-Induced Colonic Hypersensitivity in the Irritable Bowel Syndrome: The Role of Bowel Habit, Sex, and Psychologic Factors. Clinical Gastroenterology and Hepatology, 2007, 5, 201-208.	4.4	72
300	Altered Rectal Perception in Irritable Bowel Syndrome Is Associated With Symptom Severity. Gastroenterology, 2007, 133, 1113-1123.	1.3	213
301	New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Digestive and Liver Disease, 2007, 39, 201-215.	0.9	121
302	Nutritional aspects in patients with functional gastrointestinal disorders and motor dysfunction in the gut. Digestive and Liver Disease, 2007, 39, 495-504.	0.9	9
303	Nutrient-dependent enhancement of rectal sensitivity in irritable bowel syndrome (IBS). Neurogastroenterology and Motility, 2007, 19, 20-29.	3.0	75
304	Percutaneous implantation of gastric electrodes – a novel technique applied in animals and in patients. Neurogastroenterology and Motility, 2007, 19, 103-109.	3.0	34
305	CD4+CD25+regulatory T cells in irritable bowel syndrome patients. Neurogastroenterology and Motility, 2007, 19, 119-125.	3.0	36
306	Elevated motility-related transmucosal potential difference in the upper small intestine in the irritable bowel syndrome. Neurogastroenterology and Motility, 2007, 19, 812-820.	3.0	37

#	Article	IF	CITATIONS
307	Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III. Alimentary Pharmacology and Therapeutics, 2007, 26, 953-961.	3.7	66
308	Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis. Scandinavian Journal of Gastroenterology, 2006, 41, 54-59.	1.5	54
309	Gastrointestinal symptoms in patients with liver cirrhosis: Associations with nutritional status and health-related quality of life. Scandinavian Journal of Gastroenterology, 2006, 41, 1464-1472.	1.5	109
310	Health-Related Quality of Life in Patients Attending a Gastroenterology Outpatient Clinic: Functional Disorders Versus Organic Diseases. Clinical Gastroenterology and Hepatology, 2006, 4, 187-195.	4.4	96
311	The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. Liver International, 2006, 26, 840-845.	3.9	176
312	Discontinuation of proton pump inhibitors in patients on longâ€ŧerm therapy: a doubleâ€blind, placeboâ€controlled trial. Alimentary Pharmacology and Therapeutics, 2006, 24, 945-954.	3.7	155
313	Gastric electrical stimulation for intractable vomiting in patients with chronic intestinal pseudoobstruction. Neurogastroenterology and Motility, 2006, 18, 823-830.	3.0	39
314	Use and abuse of hydrogen breath tests. Gut, 2006, 55, 297-303.	12.1	351
315	Hypnosis for Irritable Bowel Syndrome:The Quest for the Mechanism of Action. International Journal of Clinical and Experimental Hypnosis, 2006, 54, 65-84.	1.8	23
316	Functional findings in irritable bowel syndrome. World Journal of Gastroenterology, 2006, 12, 2830.	3.3	68
317	Fatigue is not a specific symptom in patients with primary biliary cirrhosis. European Journal of Gastroenterology and Hepatology, 2005, 17, 351-357.	1.6	41
318	Effects of long-term treatment with oxytocin in chronic constipation; a double blind, placebo-controlled pilot trial. Neurogastroenterology and Motility, 2005, 17, 697-704.	3.0	77
319	High interdigestive and postprandial motilin levels in patients with the irritable bowel syndrome. Neurogastroenterology and Motility, 2005, 17, 51-57.	3.0	29
320	Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology, 2005, 40, 1090-1094.	1.5	60
321	Inflammation as a cause of functional bowel disorders. Scandinavian Journal of Gastroenterology, 2005, 40, 1140-1148.	1.5	32
322	A Controlled Study of Colonic Immune Activity and β7 Blood T Lymphocytes in Patients With Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2005, 3, 980-986.	4.4	88
323	Delay in gastric emptying in patients with chronic renal failure. Scandinavian Journal of Gastroenterology, 2004, 39, 516-520.	1.5	79
324	Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress. Gut, 2004, 53, 1102-1108.	12.1	250

#	Article	IF	CITATIONS
325	Quality of Life and Illness Costs in Irritable Bowel Syndrome. Digestion, 2004, 69, 254-261.	2.3	31
326	Fatigue in patients with primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology, 2004, 39, 961-968.	1.5	95
327	Oxytocin stimulates colonic motor activity in healthy women. Neurogastroenterology and Motility, 2004, 16, 233-240.	3.0	42
328	Treatment With Hypnotherapy Reduces the Sensory and Motor Component of the Gastrocolonic Response in Irritable Bowel Syndrome. Psychosomatic Medicine, 2004, 66, 233-238.	2.0	91
329	Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors. Alimentary Pharmacology and Therapeutics, 2003, 17, 279-287.	3.7	25
330	Functional dyspepsia: evaluation and treatment. Gastroenterology Clinics of North America, 2003, 32, 577-599.	2.2	17
331	Visceral hypersensitivity and relation to symptoms in the irritable bowel syndrome (IBS). Gastroenterology, 2003, 124, A14.	1.3	1
332	Patients with Chronic Renal Failure Have Abnormal Small Intestinal Motility and a High Prevalence of Small Intestinal Bacterial Overgrowth. Digestion, 2003, 67, 129-137.	2.3	87
333	Effects of Duodenal Lipids on Gastric Sensitivity and Relaxation in Patients with Ulcer-Like and Dysmotility-Like Dyspepsia. Digestion, 2003, 67, 209-217.	2.3	27
334	Unsuppressed Postprandial Phasic Contractility in The Proximal Stomach in Functional Dyspepsia: Relevance To Symptoms. American Journal of Gastroenterology, 2003, 98, 2169-2175.	0.4	48
335	Small Intestinal Motility Disturbances and Bacterial Overgrowth in Patients With Liver Cirrhosis and Portal Hypertension. American Journal of Gastroenterology, 2003, 98, 1362-1370.	0.4	166
336	Relevance of ineffective oesophageal motility during oesophageal acid clearance. Gut, 2003, 52, 784-790.	12.1	206
337	Overuse of acid suppressant drugs in patients with chronic renal failure. Nephrology Dialysis Transplantation, 2003, 18, 570-575.	0.7	62
338	Quality of life in irritable bowel syndrome: measurement techniques and relevance of current knowledge. Expert Review of Pharmacoeconomics and Outcomes Research, 2003, 3, 75-88.	1.4	7
339	Abnormal levels of neuropeptide Y and peptide YY in the colon in irritable bowel syndrome. European Journal of Gastroenterology and Hepatology, 2003, 15, 55-62.	1.6	40
340	Acid infusion enhances duodenal mechanosensitivity in healthy subjects. American Journal of Physiology - Renal Physiology, 2003, 285, G309-G315.	3.4	39
341	On-Demand Treatment in Patients with Oesophagitis and Reflux Symptoms: Comparison of Lansoprazole and Omeprazole. Scandinavian Journal of Gastroenterology, 2002, 37, 642-647.	1.5	48
342	The prevalence of gastrointestinal symptoms in patients with chronic renal failure is increased and associated with impaired psychological general well-being. Nephrology Dialysis Transplantation, 2002, 17, 1434-1439.	0.7	107

#	Article	IF	CITATIONS
343	Physical activity and the gastrointestinal tract. European Journal of Gastroenterology and Hepatology, 2002, 14, 1053-1056.	1.6	72
344	Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. American Journal of Gastroenterology, 2002, 97, 389-396.	0.4	406
345	Coordination between intestinal motility and secretion in patients with diarrhea-prone and constipation-prone irritable bowel syndrome (IBS). Gastroenterology, 2001, 120, A713.	1.3	1
346	Food-Related Gastrointestinal Symptoms in the Irritable Bowel Syndrome. Digestion, 2001, 63, 108-115.	2.3	442
347	Quality of Life in Patients with Irritable Bowel Syndrome Seen in Referral Centers Versus Primary Care: The Impact of Gender and Predominant Bowel Pattern. Scandinavian Journal of Gastroenterology, 2001, 36, 545-552.	1.5	154
348	Impact of Sex and Psychological Factors on the Water Loading Test in Functional Dyspepsia. Scandinavian Journal of Gastroenterology, 2001, 36, 725-730.	1.5	34
349	An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut, 2001, 48, 20-27.	12.1	179
350	Abnormal propagation pattern of duodenal pressure waves in the irritable bowel syndrome (IBS) [correction of (IBD)]. Digestive Diseases and Sciences, 2000, 45, 2151-2161.	2.3	79
351	Irritable bowel syndrome with foodâ€related symptoms: Future directions in the clinical management. United European Gastroenterology Journal, 0, , .	3.8	4